Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Receptor tyrosine kinase inhibitors trametinib and axitinib effectively target the neoplastic component of giant cell tumor of bone in vitro

Background: Giant cell tumor of bone (GCTB) is an intermediate osteolytic neoplasm characterized by a high rate of local recurrence. The tumor comprises two main cell populations: neoplastic stromal cells and osteoclast-like giant cells. Current adjuvant therapies primarily target osteoclast-like giant cells but have limited activity against the neoplastic stromal cells that drive tumor growth…

We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.

Read the original at biorxiv.org →

More in Health & Medicine

More from Tuesday 6 October →